Press Releases

Press Releases

or

January 8, 2016
U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody BEIJING, Jan. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that the
November 8, 2015
BOSTON — Treatment with BGB-290, a new, investigational, highly selective inhibitor of PARP1/2, was safe, tolerable, and yielded clinical responses in patients with advanced ovarian cancer, according to data from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on
October 12, 2015
BGB-283 is a novel RAF dimer inhibitor that targets both B-RAF and K-RAS/N-RAS mutated cancers BEIJING, BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient
September 30, 2015
BEIJING, BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the hiring of highly regarded industry veteran Changzhen Wu as Head of Manufacturing Operations. Mr.